



Chronic kidney disease (CKD) is defi ned as kidney damage or a glomerular 
fi ltration rate (GFR) of <60 ml/min/1.73 m2 for 3 months or more, 
irrespective of the cause.(1) Kidney damage may be indicated by the 
presence of abnormalities of the composition of blood or urine 
(e.g. proteinuria or albuminuria on random urine specimens), or by the 
presence of abnormalities on renal imaging; GFR should be estimated 
from serum creatinine using prediction equations like the Cockcroft Gault 
formula or the Modifi cation of Diet in Renal Disease (MDRD) equation. 
It is worth noting that the diagnosis of CKD does not require 24-hour 
urine collections for creatinine clearance or protein quantifi cation. 
The global epidemic of 
chronic kidney disease
Patients with CKD are classifi ed according to GFR (Table I), ranging 
from stages 1 and 2 where there are persistent urinary abnormalities 
but preserved GFR, through to stages 4 and 5, which represent advanced 
and end-stage renal disease (ESRD) respectively. In the early stages, the 
emphasis is on detection and prevention of progression, while during 
the later stages the focus includes the management of the complications 
of CKD and preparation for renal replacement therapy.
This standardised scheme for the detection and classifi cation of CKD 
has been developed during the last few years and been universally 
accepted; it will do much to raise awareness of this important problem, 
and is essential for the international development and implementation 
of clinical practice guidelines. 
THE MAGNITUDE AND CAUSES OF THE GLOBAL 
EPIDEMIC
CKD affects as many as 1 in 10 adults, or over 500 million people 
worldwide. It is a worldwide public health problem which leads 
to progressive renal failure, cardiovascular disease and premature 
death.(2, 3) The Third National Health and Nutrition Examination Surveys 
(NHANES III) in the USA found that an estimated 20 million Americans 
have CKD.(4) It is among the leading causes of death in the industrialised 
world, and the 9th most important cause of death in the USA.
Diabetic nephropathy is one of the leading causes of CKD and ESRD, 
and the global epidemic of obesity and type 2 diabetes will therefore 
result in millions of new cases of CKD. It is estimated that the number 
of people with diabetes will rise from 171 million in 2000 to 366 million 
in 2030. What is of particular concern is that the greatest burden will 
be borne by countries in the developing world, where there are usually 
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Chronic kidney disease (CKD) is defi ned as 
kidney damage or a glomerular fi ltration rate (GFR) of <60 ml/
min/1.73 m2 for 3 months or more. About one adult in ten, or over 
500 million people worldwide, are affected, with diabetic nephropathy, 
glomerulonephritis and uncontrolled hypertension being the major 
causes. The global burden of CKD is expected to increase in parallel 
with the increase in diabetes, with the developing world bearing the 
brunt of this epidemic. 
The major consequences of CKD are the development of end-stage 
renal disease (ESRD) and, even more frequently, premature death 
from cardiovascular disease. This results from a markedly increased 
prevalence as well as a higher case fatality rate. CKD is increasingly 
being recognised as a very strong risk factor for cardiovascular 
disease, justifying lower targets for blood pressure and lipid control. 
Apart from the frequent presence of traditional risk factors, 
these patients often suffer from nontraditional factors such as 
hyperphosphataemia, hyperhomocysteinaemia, malnutrition, chronic 
fl uid overload and anaemia.
The management of ESRD is extremely costly, and it is therefore not 
surprising that most patients on treatment are to be found in high 
income countries. In many African countries there is little or no 
treatment available. The focus has therefore turned to the early 
detection and treatment of CKD to prevent progression to ESRD 
and to decrease the morbidity and mortality from cardiovascular 
disease. Several international initiatives have been launched in 




TABLE 1: Defi nition and classifi cation of chronic kidney disease*
 1 Kidney damage# with normal or increased GFR ≥90
 2 Kidney damage with mild decrease in GFR 60-89
 3 Moderate decrease in GFR 30-59
 4 Severe decrease in GFR 15-29
 5 Kidney failure <15 or dialysis
 Stage Description GFR in ml/min/1.73m2 
*  Requires the presence of kidney damage or a decrease in GFR for ≥3 months.
#   Indicated by the presence of abnormalities of the composition of blood or urine (e.g. proteinuria, 
albuminuria, haematuria), or structural abnormalities. Patients found to have a GFR of 60-89 ml/
min/1.73 m2 without one of these markers should not be considered to have CKD and need not be 
subjected to further investigation.
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scant resources available to deal with the problem. The largest relative 
increases will occur in the Middle East, sub-Saharan Africa and India. In 
absolute numbers, the countries with the largest projected numbers of 
cases in 2030 will be India (79.4 million), China (42.3 million) and the 
USA (30.3 million).(5) It is therefore imperative that the focus be turned 
to the prevention of CKD, and the slowing of the progression of the 
early stages of CKD to ESRD with its serious and costly complications.
Chronic glomerulonephritis and interstitial nephritis cause most cases 
of chronic kidney disease in developing countries because of the high 
prevalence of infections. Streptococcal infections are common in Africa, 
while tuberculosis is a particular problem in causing CKD in the Middle 
East and India. In Africa the hepatitis B and C viruses, and increasingly 
HIV, are important causes of CKD. Parasitic infections may cause 
ureteric obstruction (e.g. schistosomiasis), interstitial nephritis (visceral 
leishmaniasis) and glomerulonephritis (malaria, fi lariasis, schistosomiasis).(6)
EXCESS MORBIDITY AND MORTALITY FROM         
CARDIOVASCULAR DISEASE
All patients with CKD, irrespective of the stage, have an increased risk 
of death from heart and cerebrovascular disease.(7) The relative risk of 
cardiovascular disease increases from about 1.5 among patients with 
isolated proteinuria to almost 500 among young patients on chronic 
dialysis.(6, 8) A patient with CKD is far more likely to succumb to 
cardiovascular disease than to progress to end-stage renal disease 
(ESRD) requiring dialysis or transplantation. In those who do reach 
ESRD and are included in dialysis and transplant programmes, CVD 
mortality is 10 to 30 times higher than in the general population, despite 
stratifi cation for sex, race, and the presence of diabetes.(8) The high 
mortality rate is likely due to both a high case fatality rate and a high 
prevalence of CVD. Mortality 1 and 2 years after myocardial infarction 
was 59% and 73% in dialysis patients, which is much higher than that 
expected in the general population, even in subjects with comorbid 
conditions such as diabetes.(9) Anavekar et al. examined the impact of 
renal function on cardiovascular outcomes after myocardial infarction in 
over 14 000 patients as part of the Valsartan in Acute Myocardial 
Infarction Trial (VALIANT).(10) Decreasing GFRs were associated with 
increasing mortality rates (Figure 1). Three-year mortality was 14.1% in 
the group with an estimated GFR (in ml/min/1.73 m2) of ≥75.0, 20.5% 
with a GFR of 60.0-74.9, 28.9% when GFR was 45.0-59.9 and 45.5% 
when GFR was <45.0.
The tremendous burden of cardiovascular disease in patients with CKD 
is attributed to the frequent presence of traditional factors, such 
as hypertension and dyslipidemia, as well as to nontraditional factors 
such as hyperphosphataemia and soft tissue calcifi cation, hyper-
homocysteinaemia, infl ammation, malnutrition, chronic fl uid overload, 
anaemia and other conditions.
The presence of CKD, whether it is manifested by proteinuria or 
reduced glomerular fi ltration rate (GFR), is now acknowledged as an 
independent risk factor for cardiovascular disease events (CVD) in the 
most recent report from the Joint National Committee on Prevention, 
Detection, and Treatment of High Blood Pressure (JNC VII) and in a 
position statement of the American Heart Association.(11, 12) Patients 
with CKD are considered to be in the highest-risk group by JNC VII and 
the US National Kidney Foundation, with JNC VII including CKD as a 
“compelling” indication for optimal blood pressure control, justifying 
lower target blood pressure and treatment with specifi c antihypertensive 
agents. Both the US National Kidney Foundation and the American 
Heart Association recommend that patients with CKD be included in 
the highest-risk group for treatment of dyslipidaemia, justifying a lower 
target low-density lipoprotein cholesterol level.(12)
MALNUTRITION, INFLAMMATION AND                 
ATHEROSCLEROSIS
Protein-energy malnutrition and infl ammation are common in patients 
with chronic kidney disease and worsen with progression toward end-
stage renal disease. These are major predictors of poor clinical outcome, 
as refl ected by the strong association between hypoalbuminaemia and 
cardiovascular disease. Among dialysis patients, traditional indicators of 
overnutrition (high cholesterol or body mass index (BMI)), which are 
risk factors for cardiovascular disease in the general population, are 
associated with better outcomes, while a low BMI and low cholesterol 
or creatinine are risk factors for a poor outcome. These paradoxical 
relationships between nutritional markers and outcome are referred to 
as “reverse epidemiology”. 
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In the Dialysis Outcomes and Practice Patterns Study (DOPPS), which 
involves 12 countries, nutrition-related parameters associated with increased 
mortality included low BMI, low subjective global assessment (SGA) score, 
and hypoalbuminaemia. Mortality risk was increased 1.38 times with serum 
albumin levels below 35 g/l. In the US patient cohort there was a 2.12-fold 
increase of the relative risk of death for the lowest quartile (serum albumin 
<33 g/l) compared with the highest quartile (>40 g/l). 
It has been suggested that infl ammation is the cause of both malnutrition 
and CVD. The terms malnutrition-infl ammation complex syndrome 
(MICS) and malnutrition-infl ammation-atherosclerosis (MIA) syndrome 
have been coined to indicate this interaction and the important 
contribution of both of these conditions to poor clinical outcome.(13-15) 
Causes of infl ammation in dialysis patients include, among others, 
exposure to dialysis membranes or peritoneal dialysis fl uid, poor water 
quality, peritonitis, and other infections. So far no randomised clinical 
trials have specifi cally examined the effect of nutritional or anti-
infl ammatory interventions on outcomes. It still remains unclear 
whether the association with worse outcomes is related to malnutrition 
at the time of initiation of dialysis or whether it is secondary to changes 
in nutritional status of ESRD patients over time.(16) 
TREATMENT FOR END-STAGE RENAL DISEASE            
Worldwide there are well over 1.3 million people on maintenance 
dialysis, and this number is projected to exceed 2 million by 2010.(17) 
Haemodialysis (89%) is much more common than peritoneal dialysis 
(11%) as the treatment modality. Japan has the highest prevalence rate 
of ESRD in the world, at 1 857 per million population (pmp) in 2004 
followed by Taiwan with 1 706. In the USA 104 364 new dialysis 
and transplant patients began ESRD therapy in 2004, an incidence of 
339 pmp. More than 470 000 patients were on treatment for ESRD in 
the USA on 31 December 2004, a prevalence rate of 1542 pmp - 
335 963 were on dialysis, and 136 136 had a functioning transplant.(18) 
As prevalence of ESRD is a function of incidence and deaths, and if we 
assume a similar annual incidence across most countries of the world 
(it is estimated at 150 per million population in developing countries)(6), 
then the wide variation in prevalence mainly refl ects differences in 
survival, which in turn results from the differences in the availability of 
dialysis and transplantation. This provision of renal replacement services 
(and prevalence of ESRD) correlates well with income per capita, 
especially in lower income countries.(17)
Given the costs of treating ESRD, it is not surprising that most of the 
world’s dialysis patients are being treated in high income countries, with 
52% from just four countries: the USA, Japan, Brazil and Germany. Over 
6% of the US Medicare budget is spent on ESRD, with total annual costs 
for ESRD reaching $32.5 billion. Based on the US average of around 
$66 000 per patient per annum, it is estimated that 1 trillion dollars 
would be needed to care for ESRD patients worldwide from 2001 
to 2010.(19) 
Barsoum points out that renal replacement therapy represents an 
unaffordable fi nancial burden for most poor countries, and often has 
negative psycho-social effects on communities in these countries.(6) 
Frequently, patients undergoing chronic dialysis are only partially 
rehabilitated, and remain unable to work. Dialysis is often ineffi cient 
(due to resource limitations); essential treatments such as erythropoietin, 
intravenous iron, active vitamin D, and statins may not be available; 
coexisting infections and malnutrition are common; and transportation 
diffi culties often result in noncompliance. 
In countries in which the GDP per capita is below US$10 000 there is 
a signifi cant correlation between GDP and ESRD prevalence. In India 
and Pakistan, less than 10% of patients with ESRD are offered renal 
replacement therapy and the majority of these stop treatment because 
of cost constraints within the fi rst three months.(20) Treatment rates in 
North Africa vary from 30 to 186.5 per million population where there 
are established programmes - Algeria 78.5, Egypt 129.3, Libya 30, 
Morocco 55.6, and Tunisia 186.5 pmp. Services are mainly available in 
the urban areas. In sub-Saharan Africa, a conservative approach to 
therapy most often applies. Few patients can afford chronic dialysis and 
renal transplantation is often not available.(21)
In South Africa, no current information is available on the numbers or 
the outcomes of patients with CKD or ESRD. The last formal report 
from the SA Dialysis and Transplant Registry was in 1994 and revealed 
a prevalence of 99 pmp (3 399 patients) with half of these being on 
dialysis and half having functioning grafts.(21) Two-thirds of the patients 
on dialysis were on haemodialysis and one-third on peritoneal dialysis. 
It is interesting to examine the prevalence data of countries who have 
similar gross national incomes per capita (GNIPC) to our own - South 
Africa has a GNIPC of $4 960, Malaysia $4 960, Turkey $4 710 and 
Thailand $2 750. In 2004 Malaysia had an ESRD prevalence rate per 
million of 522 (total 13 348 patients), Turkey 433 (31 251), and Thailand 
243 (15 083).(18) There are no comparable data available for South 
Africa; however, the national Dialysis and Transplant Registry is currently 
being reestablished as a joint initiative of the South African Renal and 
Transplantation Societies.
In Malaysia, where renal replacement therapy has seen an exponential 
growth since 1990,(22) this increase has been coupled to the growth in 
the country’s income per capita. In recent years greater numbers of 
diabetics (51% of new patients in 2003) and older patients have been 
admitted to their programme. It would seem reasonable that the 
resources made available for renal replacement therapy in the public 
sector in South Africa be linked to our GNIPC and that, at the present 
time, a prevalence rate of 200-300 pmp could be expected.
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TREATING CKD: POOR OUTCOMES AND                
VARIATIONS IN CLINICAL PRACTICE
There is convincing evidence that the adverse complications of CKD 
can be prevented or delayed by effective treatment of the earlier stages 
of CKD, using strategies that include smoking cessation, salt restriction, 
increasing physical activity, maintenance of a healthy weight, reduction in 
proteinuria, good blood pressure control and blockade of the renin-
angiotensin system (Figure 2).(23-25) 
Many studies have confi rmed that ACE inhibition or the use of 
angiotensin receptor blockers is protective through combined 
antihypertensive and antiproteinuric effects. The group of Remuzzi(26) 
has suggested that aggressive medical treatment to achieve multi-
factorial risk factor reduction can normalize or even reverse the annual 
rate of loss of renal function. Wendy Hoy, working with an Australian 
Aboriginal community, showed marked reductions in natural deaths 
due to renal and cardiovascular causes after instituting a prevention and 
treatment programme.(27)
There is, however, much variability in the translation of research fi ndings 
to improvements in clinical practice. Within the nephrology community, 
differences in renal patient survival in different countries came to the 
fore in 1989 at the Dallas symposium on morbidity and mortality of 
dialysis patients, with the USA recording the highest all-cause annual 
mortality (22-24%).(28) For a patient with CKD in the USA, the outcome 
was worse than for an equivalent patient with a diagnosis of colon or 
prostate cancer.(29) It was thought that differences in practice patterns 
could be responsible for these differences in outcomes. The Third 
National Health and Nutrition Examination Surveys (NHANES III) in 
the USA revealed that only 27% of patients with CKD had a blood 
pressure < 140/90 mmHg, and a majority of patients had severe anaemia 
(mean haematocrit 27.7%), with only one-quarter being prescribed 
erythropoietin despite insurance cover being available for most of 
them. Despite the clear benefi ts of renal transplantation, most eligible 
patients had not been placed on a transplant waiting list 6 months after 
beginning dialysis. Lastly, more than 50% of patients on the US ESRD 
programme were considered malnourished.(29)
While we lack good data for South Africa, there is no reason to believe 
that we do not have similar problems, with failure to reach therapeutic 
targets and lack of awareness of clinical practice guidelines, or with 
guidelines not being effectively implemented.(30) We must continue to 
strive for the successful implementation of rigorously developed 
evidence-based clinical practice guidelines, as this offers a way of 
reducing variability of care and improving patient outcomes.
EVIDENCE-BASED GUIDELINES AND INITIATIVES 
TO IMPROVE GLOBAL OUTCOMES 
Given that there is general consensus that CKD represents a major 
global public health problem, effective action is required at national and 
international levels, and cooperation across disciplines is essential. 
Several such initiatives are briefl y described below, which represent an 
encouraging response to this urgent call to action.
K/DOQI
In 1999 the Kidney Disease Outcomes Quality Initiative (K/DOQI) was 
launched by the US National Kidney Foundation – broadening the 
FIGURE 2: Effect of BP and proteinuria on renal survival
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scope of an earlier project to include all patients with kidney disease, 
from the earliest stages of kidney damage to end-stage kidney failure 
requiring dialysis and transplantation. The European Renal Association-
European Dialysis and Transplantation Association have produced the 
European Best Practice Guidelines, and clinical practice guidelines have 
also been developed by the Canadian Society of Nephrology, the 
United Kingdom Renal Association, and the Australian and New Zealand 
Society of Nephrology.(2) 
While there may be regional differences in risk factors and in available 
resources, the complications and problems of patients with kidney 
disease are universal. It is increasingly being felt that a uniform, global 
and multi-disciplinary approach to developing and implementing clinical 
practice guidelines is required. 
KDIGO
A new global organisation, Kidney Disease: Improving Global Outcomes 
(KDIGO), has been formed in an attempt to “improve the care and 
outcomes of kidney disease patients worldwide through promoting 
coordination, collaboration and integration of initiatives to develop and 
implement clinical practice guidelines”(2). The KDIGO board of directors 
includes world leaders in nephrology, with representation from North 
and South America, Europe, Africa and the Far East. Different work 
groups will focus on matters such as (i) a uniform system of evidence 
rating, (ii) the adoption of a common evaluation, classifi cation and 
nomenclature for CKD worldwide, (iii) the establishment of a database 
of currently available guidelines, (iv) the implementation of guidelines, 
(v) development efforts in regions without guidelines, and (vi) fostering 
coordination between K/DOQI and the European Best Practice 
Guidelines. 
KHDC
The International Society of Nephrology (ISN) has designed a 
programme for the detection and management of kidney disease, 
hypertension, diabetes and cardiovascular disease (KHDC) in developing 
countries. The aims are to identify the individuals with these diseases by 
community-based or selective screening programmes and then to 
provide medical management including health education, lifestyle 
modifi cation and pharmacological treatment in order eventually to 
reduce mortality and end-stage kidney disease. The documentation can 
be downloaded from the ISN website at http://www.nature.com/isn/
education/guidelines/isn/full/ed_051027_2.html. 
ISN
The International Society of Nephrology provides funding for research 
and prevention programmes, and through its Commission for the 
Global Advancement in Nephrology (COMGAN) has been running a 
very successful fellowship programme which provides nephrological 
training at advanced institutions to physicians from emerging countries, 
with the ultimate goal of improving the standards in the Fellows’ home 
countries upon their return. Through their Continuing Medical Education 
(CME) programme, COMGAN reaches some 14 000 doctors and 
health care practitioners in the emerging world annually. Their Sister 
Renal Center programme was launched in 1997 to enhance cooperation 
between nephrology centers worldwide. It aims to advance the practice 
of nephrology in the developing world by linking renal units there with 
centers of excellence. Other notable initiatives by the ISN include the 
provision of travel grants to major congresses, a Visiting Scholars 
programme which enables senior physicians and/or scientists to spend 
6 weeks to 3 months at an institution in the developing world, and a 
Library Enhancement programme.
The Bellagio 2004 Declaration
In 2004 the International Society of Nephrology convened a 
multidisciplinary group of expert physicians and public health leaders 
from around the world to develop strategies to address CKD based on 
awareness, early detection and effective treatment.(31) There was 
representation from the World Heart Federation, International Diabetes 
Federation, International Atherosclerosis Federation, and the 
International Society of Hypertension. Global perspectives on diabetes 
and cardiovascular and renal diseases were presented, with special 
emphasis on China, India, Latin America and Africa. Delegates agreed 
that an integrated global approach to chronic vascular diseases is 
needed and resolved to establish a 5-year plan for the prevention and 
treatment of chronic vascular diseases, including public advocacy, 
advising international and national agencies, and improving education 
and the practice of established approaches.
The 2004 WHO report on Preventing Chronic Diseases
In this report(32) the WHO emphasises the fact that the burden of 
chronic disease will be borne mainly by low and middle income 
countries. They point out that there is no excuse for allowing chronic 
diseases to continue taking millions of lives each year when the scientifi c 
understanding of how to prevent these deaths is available now. Bold 
action is required, especially in the context of competing priorities.
CONCLUSION                                                                    
It is important that we, in the developing world, do not fall into the trap 
of thinking that all our energies and resources should be poured into 
fi ghting infectious diseases like HIV/AIDS, tuberculosis and malaria. The 
data is clear that chronic, non-communicable diseases represent a 
terrible (and increasing) burden, causing 60% of deaths across the 
world. Of these deaths, 80% occur in middle and lower income 
countries, home to most of the world’s population.(32)
The scientifi c knowledge to address these challenges is already available. 
Measures to achieve prevention, or control the early stages of disease, are 
inexpensive and effective. However, they require large, coordinated, national 
programmes. Government “buy-in” and cooperation across our various 
medical disciplines is, therefore, essential if we are to prevent millions of 
premature deaths from heart disease, stroke, ESRD and diabetes.
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